Fed chief: “Need to see several months of inflation reduction”


From vision to action – thermostable vaccines

Published: June 21, 2022, 11:18 a.m. Updated: July 7, 2022, 10:33 a.m.New CEO at Ziccum: Ann GidnerZiccum AB’s LaminarPace technology aims to solve one of the global pharmaceutical industry’s most pressing challenges – to formulate thermostable vaccines that do not require refrigeration or freezing in the cold chain. The new CEO Ann Gidner explains how Ziccum is starting a new phase of focused industrial development. On March 11, 2020, the pharmaceutical industry entered a new era, when the WHO declared COVID-19 a global pandemic. – New vaccines were developed amazingly quickly. That drive and willingness to invest continues, which means we no longer have to sell the great benefits of thermostable vaccines. Now is the time for implementation, in our work with pharmaceutical companies and CDMOs, says Ann Gidner.From vision to actionWith over 25 years of industry experience, during her first month as CEO, Ann Gidner has put a sharper focus on Ziccum’s projects and pipeline work. The company has concentrated its project portfolio on three high-value ongoing pilot and evaluation studies; two with leading pharmaceutical companies and one with a large vaccination research institute in the Nordics. Ziccum is now also prioritizing three important, high-potential vaccine platforms. Included among these is mRNA, which is considered by many to represent a new era in vaccine technology. Explore Ziccum’s three key vaccine platforms. Strong focus on mRNAZiccum has also made large strategic investments in new facilities and equipment for mRNA/LNP material (Lipid Nanoparticles). LaminarPace has already achieved positive results with previous dry formulations of LNP materials, which were the critical delivery vehicles that enabled the two Pfizer-BioNTech- and Moderna COVID-19 vaccines. – Our work with LNP materials is exciting. At first, people were skeptical about mRNA COVID-19 vaccines. However, the exceptional drive, research and investment around vaccines created entirely new possibilities. We have been encouraged by the results we have achieved so far, says Ann Gidner.Read about Ziccum’s focus on mRNA vaccines.Growing industrial capacityZiccum is continuously developing LaminarPace’s industrial capabilities and striving for future GMP manufacturing status. The current system is the fourth generation, where nitrogen has replaced air to further reduce the moisture content, a new sealed powder collector to increase safety and an advanced set of sensors to measure the drying flow.– Other drying techniques use either extremely high (+80 °C) or low temperatures (-80 °C). This is harmful to temperature-sensitive vaccines and biological products. LaminarPace is unique. It dries gently, at room temperature and with minimal spillage. I have brought several technologies and products to market and to license agreements. Therefore, I am convinced that LaminarPace has excellent potential, says Ann Gidner.Read more about LaminarPace’s technology development.About Ziccum
Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum’s patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine substances at room temperature with minimal spillage. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain. Read more about Ziccum here.The article is produced by Brand Studio in collaboration with Ziccum and not an article by Dagens industri

Click to rate this post!
[Total: 0 Average: 0]
Next Post

Coinbase shares surge 35% after BlackRock partnership announcement

Behind the partnership announcement with investment giantCoinbase shares are demonstrating unusual trading volume. During the months of crypto market downturn, Coinbase has seen several scandals, most recently with the exchange’s former manager being arrested for insider trading and the SEC investigating the platform’s listingsuntil news that the company would sell […]

Subscribe US Now